<DOC>
	<DOCNO>NCT02643641</DOCNO>
	<brief_summary>BM32 product immunotherapy grass pollen allergy . It consist 4 different recombinant protein ( BM321 , BM322 , BM325 BM326 ) adsorb alhydrogel . This prospective , double-blind . placebo control , mono-centric trial investigates level allergen specific IgG antibody follow 3 , 4 5 subcutaneous injection grass pollen season .</brief_summary>
	<brief_title>Effect Different Pre-seasonal BM32 Dosings Induction Protective Immune Response</brief_title>
	<detailed_description>The aim study optimize immunization schedule - moving last injection begin grass pollen season study arm order ensure high possible IgG4 level need - i.e . peak grass pollen season , - administration 3 pre-seasonal injection order build sufficiently high level IgG4 already first year treatment , - dose begin grass pollen season establish safety set The effect optimize immunization schedule induction IgG4 immune response surrogate parameter efficacy study . The Total Nasal Symptom Score ( TNSS ) treatment Combined Symptom-Medication Score ( SMS ) grass pollen season evaluate secondary endpoint . This allow intra-individual comparison seasonal symptom data responsiveness chamber setting .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>The subject grass pollen allergic otherwise healthy . Healthy subject define individual free clinically significant illness disease determine medical history ( include family ) , physical examination , laboratory study , test . They age 18 60 year inclusive . They history seasonal allergic rhinitis ( SAR ) grass pollen . They normal electrocardiogram without clinically significant abnormality . They exhibit moderate severe response approximately 1500 grass pollen grains/m3 first 2h Vienna Challenge Chamber , define nasal symptom score ( TNSS ) least 6 . ( Nasal symptom score sum nasal obstruction , rhinorrhoea , itchy nose sneezing , score scale 0 3 ) . They positive skin prick test wheal diameter &gt; 5mm grass pollen extract screen visit . They positive serum IgE test timothy grass pollen rPhl p 1+rPhl p 5 screen visit ( ImmunoCAP ≥3.5 kUA/l ; i.e ≥ class 2 ) .. There condition factor would make subject unlikely able stay chamber 6 hour . They capable give informed consent include compliance requirement restriction list consent form . They available complete study measurement Sensitization Phl p 7 Pregnant , lactate sexually active woman childbearing potential use medically accept birth control method ( pregnancy control pregnancy dipstick test ) . On examination subject find structural nasal abnormality nasal polyposis , history frequent nosebleed , recent nasal surgery ongoing upper respiratory tract infection Responsible Physician 's opinion render subject unsuitable participation study . Any respiratory disease mild stable asthma control occasional use asneeded shortacting betaagonists associate normal lung function . The subject concurrently participate participate clinical study previous month . Participation SIT trial grass pollen allergy three year prior study . Past present disease , judge investigator , may affect outcome study . These disease include , limited , cardiovascular disease , malignancy , hepatic disease , renal disease , haematological disease , neurological disease , endocrine disease pulmonary disease ( include confine chronic bronchitis , emphysema , bronchiectasis pulmonary fibrosis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Grass pollen allergy</keyword>
	<keyword>subcutaneous immunotherapy</keyword>
	<keyword>allergy vaccine</keyword>
	<keyword>dose regimen</keyword>
</DOC>